Advertisement

In-Press Preview Clinical MedicineImmunologyTherapeutics Free access | 10.1172/JCI98814

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Gina A. Montealegre Sanchez, Adam Reinhardt, Suzanne Ramsey, Helmut Wittkowski, Philip J. Hashkes, Yackov Berkun, Susanne Schalm, Sara Murias, Jason A. Dare, Diane Brown, Deborah L. Stone, Ling Gao, Thomas Klausmeier, Dirk Foell, Adriana A. de Jesus, Dawn C. Chapelle, Hanna Kim, Samantha Dill, Robert Colbert, Laura Failla, Bahar Kost, Michelle O'Brien, James C. Reynolds, Les R. Folio, Katherine R. Calvo, Scott M. Paul, Nargues Weir, Alessandra Brofferio, Ariane Soldatos, Angélique Biancotto, Edward W. Cowen, John G. Digiovanna, Massimo Gadina, Andrew J. Lipton, Colleen Hadigan, Steven M. Holland, Joseph Fontana, Ahmad S. Alawad, Rebecca J. Brown, Kristina I. Rother, Theo Heller, Kristina M. Brooks, Parag Kumar, Stephen R. Brooks, Meryl Waldman, Harsharan K. Singh, Volker Nickeleit, Maria Silk, Apurva Prakash, Jonathan M. Janes, Seza Ozen, Paul G. Wakim, Paul A. Brogan, William L. Macias, and Raphaela Goldbach-Mansky

Find articles by Sanchez, G. in: JCI | PubMed | Google Scholar

Find articles by Reinhardt, A. in: JCI | PubMed | Google Scholar

Find articles by Ramsey, S. in: JCI | PubMed | Google Scholar

Find articles by Wittkowski, H. in: JCI | PubMed | Google Scholar

Find articles by Hashkes, P. in: JCI | PubMed | Google Scholar

Find articles by Berkun, Y. in: JCI | PubMed | Google Scholar

Find articles by Schalm, S. in: JCI | PubMed | Google Scholar

Find articles by Murias, S. in: JCI | PubMed | Google Scholar

Find articles by Dare, J. in: JCI | PubMed | Google Scholar

Find articles by Brown, D. in: JCI | PubMed | Google Scholar

Find articles by Stone, D. in: JCI | PubMed | Google Scholar

Find articles by Gao, L. in: JCI | PubMed | Google Scholar

Find articles by Klausmeier, T. in: JCI | PubMed | Google Scholar

Find articles by Foell, D. in: JCI | PubMed | Google Scholar

Find articles by Jesus, A. in: JCI | PubMed | Google Scholar

Find articles by Chapelle, D. in: JCI | PubMed | Google Scholar

Find articles by Kim, H. in: JCI | PubMed | Google Scholar

Find articles by Dill, S. in: JCI | PubMed | Google Scholar

Find articles by Colbert, R. in: JCI | PubMed | Google Scholar

Find articles by Failla, L. in: JCI | PubMed | Google Scholar

Find articles by Kost, B. in: JCI | PubMed | Google Scholar

Find articles by O'Brien, M. in: JCI | PubMed | Google Scholar

Find articles by Reynolds, J. in: JCI | PubMed | Google Scholar

Find articles by Folio, L. in: JCI | PubMed | Google Scholar

Find articles by Calvo, K. in: JCI | PubMed | Google Scholar

Find articles by Paul, S. in: JCI | PubMed | Google Scholar

Find articles by Weir, N. in: JCI | PubMed | Google Scholar

Find articles by Brofferio, A. in: JCI | PubMed | Google Scholar

Find articles by Soldatos, A. in: JCI | PubMed | Google Scholar

Find articles by Biancotto, A. in: JCI | PubMed | Google Scholar

Find articles by Cowen, E. in: JCI | PubMed | Google Scholar

Find articles by Digiovanna, J. in: JCI | PubMed | Google Scholar

Find articles by Gadina, M. in: JCI | PubMed | Google Scholar

Find articles by Lipton, A. in: JCI | PubMed | Google Scholar

Find articles by Hadigan, C. in: JCI | PubMed | Google Scholar

Find articles by Holland, S. in: JCI | PubMed | Google Scholar

Find articles by Fontana, J. in: JCI | PubMed | Google Scholar

Find articles by Alawad, A. in: JCI | PubMed | Google Scholar

Find articles by Brown, R. in: JCI | PubMed | Google Scholar

Find articles by Rother, K. in: JCI | PubMed | Google Scholar

Find articles by Heller, T. in: JCI | PubMed | Google Scholar

Find articles by Brooks, K. in: JCI | PubMed | Google Scholar

Find articles by Kumar, P. in: JCI | PubMed | Google Scholar

Find articles by Brooks, S. in: JCI | PubMed | Google Scholar

Find articles by Waldman, M. in: JCI | PubMed | Google Scholar

Find articles by Singh, H. in: JCI | PubMed | Google Scholar

Find articles by Nickeleit, V. in: JCI | PubMed | Google Scholar

Find articles by Silk, M. in: JCI | PubMed | Google Scholar

Find articles by Prakash, A. in: JCI | PubMed | Google Scholar

Find articles by Janes, J. in: JCI | PubMed | Google Scholar

Find articles by Ozen, S. in: JCI | PubMed | Google Scholar

Find articles by Wakim, P. in: JCI | PubMed | Google Scholar

Find articles by Brogan, P. in: JCI | PubMed | Google Scholar

Find articles by Macias, W. in: JCI | PubMed | Google Scholar

Find articles by Goldbach-Mansky, R. in: JCI | PubMed | Google Scholar

First published April 12, 2018 - More info

J Clin Invest. https://doi.org/10.1172/JCI98814.
Copyright © 2018, American Society for Clinical Investigation

First published April 12, 2018
Abstract

BACKGROUND. Monogenic Interferon (IFN)-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN-response-gene-signature (IRS), inflammatory organ damage and high mortality. We used the janus kinase (JAK) inhibitor baricitinib with IFN-blocking activity in vitro, to ameliorate disease.

METHODS. Between October 2011 and February 2017, 10 patients with CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 with SAVI (Stimulator of IFN genes (STING)-associated vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an Expanded Access Program. Patients underwent dose-escalation, benefit was assessed by reductions in daily disease symptoms and corticosteroid requirement. Quality-of-life, organ inflammation, changes in IFN-induced biomarkers, and safety were longitudinally assessed.

RESULTS. 18 patients were treated for a mean duration of 3.0 years (1.5–4.9 years). The median daily symptom score decreased from 1.3 (IQR 0.93–1.78) to 0.25 (IQR 0.1-0.63) (P < 0.0001). In 14 patients receiving steroids at baseline, daily prednisone doses decreased from 0.44 mg/kg/day (IQR 0.31–1.09) to 0.11 mg/kg/day (IQR 0.02–0.24) (P < 0.01); 5 of 10 CANDLE patients achieved lasting clinical remission. Quality of life, height and bone mineral density Z-scores significantly improved, and IFN biomarkers decreased. Three patients discontinued, two with genetically undefined conditions due to lack of efficacy, and one CANDLE patient due to BK viremia and azotemia. The most common adverse events were upper respiratory infections, gastroenteritis, BK viruria and viremia.

CONCLUSION. On baricitinib treatment, clinical manifestations, inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies, CANDLE, SAVI and 2 other interferonopathies. Monitoring safety and efficacy is important in benefit-risk assessment.

TRIAL REGISTRATION. ClinicalTrials.gov NCT01724580 and NCT02974595.

FUNDING. NIH, NIAID, NIAMS, NIDDK, NHLBI, NINDS, and the Clinical Center. Baricitinib was provided by Eli Lilly. Eli Lilly is the sponsor of the compassionate use program.

Supplemental material

View supplement

Version history
  • Version 1 (April 12, 2018): In-Press Preview
Advertisement
Advertisement